Key result
Point-of-care hs-cTnI matches lab assays with ~84% concordance and 100% sensitivity for Type 1 MI.
Why the study?
Local analytical and clinical evaluation of point-of-care high-sensitivity cardiac troponin testing is required before implementation in emergency departments.
Does the Abbott i-STAT Alinity point-of-care hs-cTnI assay provide comparable diagnostic performance and threshold concordance to standard laboratory testing in ED patients with suspected ACS?
Observational
No
Does the Abbott i-STAT Alinity point-of-care hs-cTnI assay provide comparable diagnostic performance and threshold concordance to standard laboratory testing in ED patients with suspected ACS?
The i-STAT Alinity point-of-care high-sensitivity troponin I assay demonstrates analytical performance and clinical concordance comparable to laboratory testing, supporting its potential use for rapid ACS rule-out in the emergency department.
May support point-of-care hs-cTnI for ED rule-out; leaves open prospective outcome validation before practice change.
Background: High-sensitivity cardiac troponin (hs-cTn) testing is central to emergency department assessment of suspected acute coronary syndrome. Point-of-care hs-cTn testing may reduce turnaround time, but local analytical and clinical evaluation is required before implementation. Methods: In a single-centre real-world evaluation, paired whole-blood and plasma samples from patients with suspected acute coronary syndrome were analysed using the Abbott i-STAT Alinity point-of-care hs-cTnI assay and the Alinity laboratory hs-cTnI assay. Imprecision, method comparison, threshold concordance, diagnostic discrimination for adjudicated Type 1 myocardial infarction (MI), and potential effects of haemolysis, icterus, lipaemia and haematocrit were assessed. Results: Low-level imprecision was below 10% CV. Concordance at the <5 ng/L rule-out threshold was high (84.1%); all discordant classifications reflected higher POCT values, with no false-negative rule-outs. Both assays showed similar discrimination for adjudicated Type 1 MI and 100% observed sensitivity and negative predictive value at the 5 ng/L threshold, although confidence intervals were wide. POCT specificity was lower than laboratory specificity. Method comparison showed a modest positive POCT bias, and regression analyses did not identify clinically meaningful effects of haemolysis, icterus, lipaemia or haematocrit. Conclusion: The Abbott i-STAT Alinity POCT hs-cTnI assay demonstrated analytical performance and clinical concordance supportive of local implementation, with similar diagnostic discrimination to the Alinity laboratory hs-cTnI assay in a small cohort. Larger prospective studies are needed to confirm clinical safety and workflow impact.
No takes yet. Share an insight, caveat, or question.
Burns et al. (2026) conducted an observational in Suspected acute coronary syndrome. Abbott i-STAT Alinity point-of-care hs-cTnI assay vs. Alinity laboratory hs-cTnI assay was evaluated on Concordance at the <5 ng/L rule-out threshold and diagnostic discrimination for adjudicated Type 1 myocardial infarction. The Abbott i-STAT Alinity point-of-care hs-cTnI assay had 84.1% concordance at the <5 ng/L rule-out threshold and 100% sensitivity for Type 1 MI compared to the laboratory assay.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: